We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare and Medicaid Service’s (CMS) Timothy Stitely will become the FDA’s chief information officer, the agency announced. At the CMS, Stitely served as the director of Information Services Design & Development.
Federal policymakers should ensure the FDA has adequate resources in order to review and approve follow-on biologics in a timely and effective manner, according to American Enterprise Institute (AEI) Research Fellow Scott Gottlieb.
The Centers for Medicare and Medicaid Service’s (CMS) Timothy Stitely will become the FDA’s chief information officer, the agency announced. At the CMS, Stitely served as the director of Information Services Design & Development.
In one of the first oversight actions of the new Congress, members of the House Committee on Energy and Commerce released a letter sent to FDA Commissioner Andrew von Eschenbach announcing an inquiry into one of the agency’s contracts.
The FDA has announced two major personnel changes, moving Janet Woodcock to oversee a new office and inserting John Dyer as deputy commissioner for operations and chief operating officer of the agency.
The FDA has announced two major personnel changes, moving Janet Woodcock to oversee a new office and inserting John Dyer as deputy commissioner for operations and chief operating officer (COO) of the agency.
Alex Azar, HHS’ deputy secretary, is resigning, leaving a void in the agency’s efforts to continue implementation of the Part D prescription drug plan, sources say.
Instead of the new regulatory authority being proposed by lawmakers and embodied in a recent study by the Institute of Medicine, the FDA actually needs money to improve the science of regulation, according to the agency’s outgoing deputy commissioner for medical and scientific affairs.
Instead of the new regulatory authority being proposed by lawmakers and embodied in a recent study by the Institute of Medicine, the FDA actually needs money to improve the science of regulation, according to the agency's outgoing deputy commissioner for medical and scientific affairs.
Trey Sunderland, a senior scientist at the National Institute of Mental Health (NIMH), pleaded guilty to participating in a conflict of interest by accepting $285,000 in consulting fees from Pfizer.